As drug discovery continues to progress and adapt to modern day scientific challenges, the scope of pharmaceutical development becomes increasingly more comprehensive. Like Visikol, many research organizations are making the shift from animal models to 3D cell culture models. This poses a newfound industry need for the development of said models, especially those that are representative of complex structures – such as the blood brain barrier (BBB).
Due to specific structural and biochemical properties of the BBB, most small and large molecule drugs cannot cross over into the central nervous system (CNS) – therefore, there is significant motivation to develop a scalable and clinically relevant model for use in drug discovery.
Visikol has expanded its portfolio of 3D cell culture models with the inclusion of a BBB model. The development of this model is extremely beneficial to identifying treatments for major brain disorders – such as traumatic brain injury (TBI), brain tumors, Alzheimer’s disease (AD), etc. Through the use of induced pluripotent stem cells (iPSCs), Visikol is working to mimic the intrinsic resistance of the BBB. The iPSCs will simulate the tightly linked endothelial cell barrier bolstered by pericytes that is characteristic of the BBB. While primary cell lines were traditionally used to study the BBB due to high TEER values (a measure of epithelial cell barrier integrity and permeability), they are often difficult to obtain and cell viability can often be lower than desired. Stem cells offer a promising alternative due to their capacity to differentiate into brain endothelial cells and potential for patient specificity. However, just like in all aspects of science, there are limitations to every research route – and in the case of iPSCs, the narrow experimental window under in vivo conditions presents a considerable limitation to be considered.
Regardless of the cell source, an urgent need remains for an effective BBB model to study pharmacological solutions to brain disorders. Alzheimer’s affects 50% of people over 85, and an estimated 1.5 million Americans sustain a TBI every year – each with no defined pharmacological treatment options. As a leader in drug discovery, Visikol will continue to advance its R&D efforts to further the development of these treatments. Please reach out with any questions or inquiries today!
We use technologies like cookies to store and/or access device information. We do this to improve browsing experience and to show (non-) personalized ads. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.